Impact News +++ Why GoPro Stock Skyrocketed This Week (Fool) +++ GOPRO Aktie +3,33%

REMEGEN Aktie

>REMEGEN Aktienkurs

10.7 EUR +12.6% (Tradegate)

Ask: 11.2 EUR / 300 Stück

Bid: 10.7 EUR / 310 Stück

Tagesumsatz: 1686 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

REMEGEN Aktie über LYNX handeln

Intraday

1 Jahr

>REMEGEN Performance

1 Woche: +6,0%

1 Monat: +27,0%

3 Monate: +88,3%

6 Monate: +328,9%

1 Jahr: +612,2%

laufendes Jahr: +451,4%

>REMEGEN Aktie

Name:

REMEGEN CO. LTD YC 1

Land:

China

Sektor:

Gesundheit

ISIN/ Wkn:

CNE1000048G6 / A2QGM4

Symbol/ Ticker:

REG (Frankfurt)

Kürzel:

FRA:REG, ETR:REG, REG:GR

Index:

Webseite:

http://www.remegen.com/

Profil:

RemeGen Co., Ltd. is a biotechnology firm based in..
>Volltext..

Marktkapitalisierung:

5539.75 Mio. EUR

Unternehmenswert:

5704.55 Mio. EUR

Umsatz:

242.13 Mio. EUR

EBITDA:

-89.71 Mio. EUR

Nettogewinn:

-133.98 Mio. EUR

Gewinn je Aktie:

-0.25 EUR

Schulden:

319.56 Mio. EUR

Liquide Mittel:

152.21 Mio. EUR

Operativer Cashflow:

-63.38 Mio. EUR

Bargeldquote:

0.5

Umsatzwachstum:

33.51%

Gewinnwachstum:

35.34%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

REMEGEN

Letzte Datenerhebung:

29.08.25

>REMEGEN Kennzahlen

Aktien/ Unternehmen:

Aktien: 200.81 Mio. St.

Frei handelbar: 85.87%

Leerverk. Aktien: -

Rückkaufquote: 0.04%

Mitarbeiter: 3497

Umsatz/Mitarb.: 0.06 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: -14.7%

Bewertung:

KGV: -

KGV lG: -

KUV: 21.48

KBV: 21.57

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 71.58%

Gewinnmarge: -55.33%

Operative Marge: -52.55%

Managementeffizenz:

Gesamtkaprendite: -19.51%

Eigenkaprendite: -45.12%

>REMEGEN Peer Group

Es sind 101 Aktien bekannt.

>REMEGEN Chart & Kurs - Tradegate

>REMEGEN News

27.08.25 - 16:18	Vor Bio, RemeGen late-stage trial of telitacicept in IgA nephropathy meets primary goal (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

19.08.25 - 02:03	RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries (PR Newswire)
	YANTAI, China, Aug. 18, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. ("Santen China"), a wholly-owned......

14.08.25 - 06:15	REMEGEN Spikes 14% as Innovative Drug Telitacicept Achieves Endpoint in Major Study (AAStocks)
	REMEGEN (09995.HK) opened 4.7% higher today, and peaked at $79.5, setting a high in over 3.5 years. It last printed at $77.9, spiking 14.31%. Trading volume has increased to 15.5649 million shares, involving $1.17 billion.REMEGEN announced that the Phase III study of telitacicept, its independently developed BLyS/APRIL innovativ......

13.08.25 - 11:54	Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren′s Syndrome in China (PR Newswire)
	YANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met the primary endpoint in its Phase III clinical trial for the treatment of primary......

08.08.25 - 14:03

Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma (GlobeNewswire EN)

SHANGHAI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application (“sNDA”) for toripalimab (trade name: TUOYI®) in combination with disitamab vedotin, an antibody-drug conjugate (“ADC”) developed by RemeGen Co., Ltd. as the treatment of HER2-expressing (HER2 expression is defined as a HER2 immunohistochemistry test result of 1+, 2+, or 3+) locally advanced or metastatic urothelial carcinoma (“UC”), has been accepted by the National Medical Products Administration (“NMPA”). This is toripalimab's 13th application for marketing submitted in the Chinese mainland....

08.08.25 - 11:54	RemeGen′s Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA (PR Newswire)
	YANTAI, China, Aug. 8, 2025 /PRNewswire/ -- On August 8th, RemeGen Co., Ltd. (688331.SH/09995.HK) announces clearance of IND application by Food and Drug Administration (FDA) for phase II clinical trials for its independently-developed bispecific antibody, RC148, for the treatment of......

30.06.25 - 18:15	Vor Bio Stock Skyrockets 250% in the Past Week: Here′s Why (Zacks)
	The VOR stock soars in the past week after a licensing deal with RemeGen. The company also appoints a chief executive officer and chairman....

26.06.25 - 05:15	REMEGEN Grants Vor Bio Exclusive Development Rights for Telitacicept Outside Greater China (AAStocks)
	REMEGEN (09995.HK) announced that it will grant Vor Bio (VOR.US) a paid license for its self-developed Telitacicept with intellectual property rights, and Vor Bio will obtain the exclusive rights to develop and commercialize Telitacicept worldwide (excluding Greater China (i.e. Mainland China, Hong Kong, Macau and Taiwan)).In ad......

25.06.25 - 22:48	Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset (GlobeNewswire EN)
	Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset...

17.06.25 - 17:18	RemeGen′s Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis (PR Newswire)
	YANTAI, China, June 17, 2025 /PRNewswire/ -- On June 16, 2025, RemeGen Co., Ltd. ("RemeGen", stock symbols: 688331.SH/09995.HK) announced that telitacicept (RC18; brand name: 泰爱®) has received Orphan Drug Designation (ODD) from European Medicines Agency (EMA) for the treatment of......

16.06.25 - 05:45	Research: UBS Downgrades REMEGEN to Neutral, Raises TP to HKD63.8 (AAStocks)
	REMEGEN (09995.HK)'s stock price has already snowballed by three times YTD, surpassing the industry's 64% increase, primarily due to progress in its pipeline products and the HKD796 million share placement that alleviated the group's financial strain, according to a report issued by UBS.From a 12-month perspective, U......

27.05.25 - 10:33	RemeGen: Telitacicept for the Treatment of Generalized Myasthenia Gravis Approved in China (PR Newswire)
	YANTAI, China, May 27, 2025 /PRNewswire/ -- On May 27, RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept has officially been approved for marketing in China by the National Medical Products Administration (NMPA) for the treatment of adult patients with anti-acetylcholine......

23.05.25 - 05:00	REMEGEN Continues Rally, Hitting 2-Yr High w/ ~5% Surge; Nomura Lifts TP on Shr Placement Aiming to Raise ~HKD800M (AAStocks)
	Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

12.05.25 - 10:27	Poised to Reshape Treatment Landscape: The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ‌Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS (PR Newswire)
	YANTAI, China, May 12, 2025 /PRNewswire/ -- On May 12th, 2025, RemeGen Co., Ltd. ("RemeGen", stock symbols: 688331.SH/09995.HK) announced that its phase 3 clinical trial (Study ID: RC48-C016) on disitamab vedotin (DV, brand name: 爱地希®), the first domestically approved antibody-drug......

09.04.25 - 04:09	Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis (PR Newswire)
	YANTAI, China, April 8, 2025 /PRNewswire/ -- On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym: RC18; brand name: 泰爱®) in patients with generalized myasthenia gravis (gMG) were presented......

08.01.25 - 11:33	Published in Annals of Oncology: Disitamab Vedotin Combined with PD-1 Inhibitor is a Promising Treatment for Locally Advanced or Metastatic Urothelial Carcinoma (PR Newswire)
	YANTAI, China, Jan. 8, 2025 /PRNewswire/ -- On Janurary 7th, 2025, Annals of Oncology (IF: 56.7), a top oncology journal globally, published remarkable long-term follow-up results of a phase 1b/2 clinical trial on Disitamab Vedotin (DV) (developed by Remegen Co., Ltd) combined with......

23.12.24 - 03:45	Research: CMSI: Top Picks HANSOH PHARMA/ REMEGEN for CN Innovative Pharma Sector (AAStocks)
	Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

23.12.24 - 03:15	Research: CMSI Rates H-shrs at Cautiously Recommend on 1Q25 Strategy Outlook (AAStocks)
	CMSI's 1Q25 top picks are Amazon.com (AMZN.US), Doordash (DASH.US), Netflix (NFLX.US), MEITUAN-W (03690.HK), TENCENT (00700.HK), Tencent Music Entertainment Group (TME.US), HANSOH PHARMA (03692.HK), 3SBIO (01530.HK), REMEGEN (09995.HK), Alnylam Pharmaceuticals (ALNY.US), Thermo Fisher Scientific (TMO.US), GIANT BIOGENE (0236......

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Trenne alles, was eigentlich Geschäft ist, vom Leben. - Johann Wolfgang von Goethe

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram